Organic Active Ingredients TRIZ Cases

Isolated tetrahydrocannabivarin reduces chemotherapy-induced nausea without potentiating toxin effects.

Novel heterocyclic small molecule splicing modulators target RNA transcripts to treat neurological disorders.

Polyglycerol fatty acid esters prevent polymorphic blooming and maintain stable release kinetics for thermolabile pharmaceuticals.

Carrier molecules protect mRNA from degradation and enhance uptake into cancerous cells.

Segmenting immunomodulators into enzyme-cleavable prodrugs sustains effective drug levels locally, reducing systemic toxicity and improving patient compliance.

Antisense oligonucleotides induce targeted exon skipping in the dystrophin gene to restore functional protein expression.

Imatinib mesylate blocks the c-Kit receptor to inhibit addiction pathways, reducing withdrawal symptoms and relapse rates without severe side effects.

Chemically stabilized siRNA conjugates inhibit APOC3 expression, reducing blood lipid levels and improving profiles without off-target effects.

Serpentine channel chaotic advection produces uniform lipoplexes, resolving diffusion limitations and boosting suspension cell transfection efficiency.

3-Alkoxy-4,5-diarylthiophene-2-carboxamide derivatives resist brain penetration while maintaining peripheral CB1 receptor antagonism.

Benzopiperazine derivatives inhibit CETP to raise HDL cholesterol while lowering LDL and reducing adverse effects.

A topical composition combines magnesium and penetration enhancers to deliver active agents directly into muscle tissue.

Exosomes delivering circRNA MOTOR reverse monocyte LPS tolerance to reduce sepsis mortality.

Edaravone activates Nrf2 to promote axon regeneration, avoiding tumorigenesis risks from genetic overexpression.

OSI-632 blocks multiple signaling pathways to reduce collagen deposition while promoting hepatocyte regeneration.

Preliminary agonist treatment activates VLA-4 integrins on hematopoietic stem cells, improving engraftment efficiency while minimizing systemic toxicity.

Sterol ionizable lipids form lipid nanoparticles to overcome RNA instability and low cell permeability.

N-substituted benzenepropanamide compounds provide effective analgesic activity through polyalkylene glycol substitution.

A stable crystalline polymorph of Aspacytarabine enables reproducible manufacturing through controlled phase transitions.

Esketamine formulations limit oxidative degradant formation by storing and preparing compositions in the absence of light.

Segmented wing regions enhance stability while the central gapmer maintains activity, resolving specificity versus potency trade-offs.

Retinol-like microemulsions stimulate endogenous hyaluronic acid and mucin production to sustain ocular surface health.

Hydroxyl ketals replace d-limonene by offering adjustable properties without strong odor or flammability.

A DCI pharmaceutical preparation combines dimethylarsenic acid, indirubin, and cordycepin to inhibit cell proliferation.

Inhibiting phospholipid scramblase 1 prevents phosphatidylserine externalization, reducing microglia-mediated phagocytosis and inflammatory responses.

Pyrimidinone derivatives inhibit AKT phosphorylation, disrupting the PI3K/AKT/mTOR pathway to overcome chemotherapy resistance in cancer treatment.

Oral choline ester composition increases sleeping time and maintains sleep efficiency, reducing health expenditures from insufficient rest.

Combining mirdametinib and apilimod targets MEK and PIKfyve pathways in pancreatic cancer cells.

PTEN inhibitors drive delta-opioid receptor surface trafficking to enhance analgesic bioavailability while minimizing addiction risks.

Cyclodextrin-spermidine inclusion complexes provide controlled release of spermidine, optimizing mitotic action for oral tissue repair.

Macrocyclic lactam structure from Streptomyces somaliensis fermentation provides anti-inflammatory activity without glucocorticoid side effects.

A LIV21 protein complex kit detects cancer cells using specific antibodies and probes.

Psilocybin analogs deliver anxiolytic effects without harmful psychoactive side effects.

Optimizing non-volatile hydrocarbon oil viscosity below 70 mm²/s prevents support delamination while maintaining strong adhesive bonding.

Novel substituted heterocyclic compounds inhibit Tyk2 signaling to modulate cytokine pathways.

E-selectin inhibitor reduces inflammatory myeloid cell infiltration, stabilizing plaques and preventing rupture in cardiovascular disease treatment.

Antisense oligomer conjugates restore functional dystrophin production by inducing exon 53 skipping.

Optimized monoclonal antibodies target the SAS1B propeptide region with enhanced affinity, resolving insufficient binding specificity in existing therapies.

Modular segmentation and preliminary chiral action resolve yield and versatility contradictions in hyperforin analog production.

Azacitidine injection preparation eliminates activated carbon filtration by controlling raw material endotoxin levels, reducing production complexity.

Dual FABP4/5 inhibitors improve insulin sensitivity and reduce plasma triglycerides to treat metabolic syndrome.

Combining gelatin with at least 20% hydrophobic polymer creates a tamper-resistant matrix that extends pharmacological response duration.

A multi-ingredient food composition alleviates viral symptoms through synergistic immune enhancement.

A purine compound inhibits activated hepatic stellate cells to reduce collagen synthesis.

Deuterium substitution in pyrazolo[1,5-a]pyrimidines improves metabolic stability and bioavailability while reducing toxicity.

Fusing interferon tau with human IgG Fc fragments extends half-life and reduces toxicity against SARS-CoV-2.